MRNA 8-K 2026-11-06

Moderna, Inc. (MRNA) 8-K dated 2026-11-06 — accession 0001682852-26-000194.

Moderna, Inc. (MRNA) is a biotechnology company listed on NASDAQ. It is led by Stéphane Bancel M.B.A..

MRNA: Moderna Reports Third Quarter 2026 Financial Results and Provides Busin…

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported MRNA revenue for 2025-12-31 was $1.94B. Net income was -$2.82B. Revenue was down 39.9% from 2024-12-31 to 2025-12-31. MRNA currently screens at market cap $24.52B.

Not investment advice. The MRNA SEC hub lists recent forms. The stock page is the research view.